Form 4: United Therapeutics Director Christopher Patusky Reports Stock Transactions
SEC Form 4 Filing
Director Christopher Patusky reports acquisition of 900 shares of United Therapeutics common stock upon vesting of restricted stock units.
Summary
- On July 13, 2024, Christopher Patusky, a director of United Therapeutics Corp, acquired 900 shares of common stock.
- The acquisition resulted from the vesting of restricted stock units.
- The restricted stock units converted into common stock on a one-for-one basis.
- Patusky also indirectly owns 1,100 shares of Common Stock through a trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, and carries a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects changes in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 07/13/2024 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 07/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.